On April 25 (Monday) another meeting of the Transparency Council.
The agenda includes:
Preparation of a position on the evaluation of Keytruda (pembrolizumabum) under the drug program: "Treatment of esophageal cancer (ICD-10: C15...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
